Turn Therapeutics Inc GX-03 Phase 2 Update Transcript
Good afternoon and welcome to the Turn Therapeutics Investor Update Call. At this time, all participants are in a listen-only mode. Please be advised that today's conference is being recorded at the company's request.
I will now turn the call over to Sasha Damouni Ellis, Head of Investor Relations and Communications at Turn Therapeutics. Sasha, you may begin.
Thank you, operator. Good afternoon, and thank you all for joining us today. Earlier today, we issued a press release announcing the final Stage 2 design and data-driven expansion of the GX-03 Phase 2 program in atopic dermatitis.
Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the applicable securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs' future results, performance, or achievements to differ significantly from those expressed or implied by such
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
